GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (FRA:NB3) » Definitions » ROE % Adjusted to Book Value

Neurocrine Biosciences (FRA:NB3) ROE % Adjusted to Book Value : 3.00% (As of Dec. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Neurocrine Biosciences ROE % Adjusted to Book Value?

Neurocrine Biosciences's ROE % for the quarter that ended in Dec. 2024 was 16.00%. Neurocrine Biosciences's PB Ratio for the quarter that ended in Dec. 2024 was 5.34. Neurocrine Biosciences's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was 3.00%.


Neurocrine Biosciences ROE % Adjusted to Book Value Historical Data

The historical data trend for Neurocrine Biosciences's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences ROE % Adjusted to Book Value Chart

Neurocrine Biosciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.83 1.28 1.54 2.18 2.70

Neurocrine Biosciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.82 1.30 1.90 4.64 3.00

Competitive Comparison of Neurocrine Biosciences's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurocrine Biosciences's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Neurocrine Biosciences's ROE % Adjusted to Book Value falls into.


';

Neurocrine Biosciences ROE % Adjusted to Book Value Calculation

Neurocrine Biosciences's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=14.42% / 5.34
=2.70%

Neurocrine Biosciences's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=16.00% / 5.34
=3.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neurocrine Biosciences ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurocrine Biosciences Business Description

Traded in Other Exchanges
Address
6027 Edgewood Bend Court, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Neurocrine Biosciences Headlines

No Headlines